Cryo-Cell Reports Mixed Q1 Results: Revenue Up but Net Income Down Amid Rising Costs and Legal Disputes

Cryo-Cell International, Inc. (OTCMKTS: CCEL) is a leading player in the umbilical cord blood and tissue stem cell banking industry. The company reported its financial results for the three-month period ending February 28, 2025. Below are the key insights derived from the income statement, including both positive and negative aspects. ### Key Financial Highlights: - **Total Revenue**: $7,968,880 (up 2% from $7,852,235 in the previous year). - **Processing and Storage Fees**: $7,865,888 (slight increase). - **Public Banking Revenue**: $82,079 (up from $43,713). - **Product Revenue**: $20,913 (up from $3,000). - **Total Costs and Expenses**: $6,912,869 (down from $7,031,012). - **Cost of Sales**: $1,984,588 (includes processing and storage costs). - **Selling, General and Administrative Expenses**: $4,638,285 (up 5% year-over-year). - **Research and Development Expenses**: $98,143 (down from $502,889, indicating reduced investment in development). - **Operating Income**: $1,056,011 (up from $821,223). - **Net Income**: $282,855 (down from $556,241). - **Net Income per Share - Basic**: $0.03 (down from $0.07). - **Interest Expense**: $494,962 (significant increase from $256,459). ### Positive Aspects: - **Revenue Growth**: Revenue increased by 2%, showing resilience and slight growth in core operations. - **Cost Control**: Total costs decreased, indicating improved efficiency in managing operational expenses. - **Operating Income Increase**: Operating income rose significantly, reflecting better profitability in operations. ### Negative Aspects: - **Net Income Decline**: The drop in net income from $556,241 to $282,855 indicates challenges, likely tied to increased interest expenses. - **Increased Administrative Costs**: Significant rise in selling, general and administrative expenses, reflecting potential inefficiencies or investments that are not immediately yielding returns. - **Decline in New Clients**: A 12% decrease in the number of new domestic cord blood specimens processed could signify challenges in client acquisition or market competition. ### Additional Observations: - **Balance Sheet Insights**: The company ended the quarter with cash and cash equivalents of $223,122, down from $560,960, attributed to increased operational expenditures, including a cash dividend paid to shareholders. - **Ongoing Legal and Financial Disputes**: Cryo-Cell is embroiled in arbitration with Duke University regarding a licensing agreement, potentially impacting future revenues and expenditures. This analysis highlights both the potential for growth within Cryo-Cell and the challenges that could impact its financial health moving forward. Investors and analysts will want to monitor how the company navigates its current operations and external pressures, particularly in light of the ongoing legal issues and increased operational costs.